Compare PMM & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMM | TTRX |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.4M | 298.8M |
| IPO Year | 1994 | 2025 |
| Metric | PMM | TTRX |
|---|---|---|
| Price | $5.77 | $16.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 82.0K | ★ 91.4K |
| Earning Date | 01-01-0001 | 05-31-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.76 | $2.57 |
| 52 Week High | $6.60 | $14.50 |
| Indicator | PMM | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 21.50 | 75.45 |
| Support Level | N/A | $3.49 |
| Resistance Level | $6.35 | N/A |
| Average True Range (ATR) | 0.07 | 1.31 |
| MACD | -0.03 | 0.32 |
| Stochastic Oscillator | 3.92 | 88.29 |
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.